Hamlet BioPharma Announces the Nomination of Elisabeth Parker to its Board of Directors
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce the nomination of Dr. Elisabeth Parker to its Board of Directors. Dr. Parker's nomination will bring business development, international pharmaceutical industry networks and leadership excellence to the company and strengthen the continued growth of Hamlet BioPharma. Dr. Elisabeth Parker is currently serving as a Senior Investment Advisor for Healthcare and Life Sciences